Date Initiated: 08/26/2020
The Class is defined as all persons who purchased, for personal consumption and not for resale, one or more of the covered Neuriva products from Reckitt Benckiser or an authorized reseller in the United States, between Jan. 1, 2019, and April 23, 2021.
Date Initiated: 04/23/2021
The Class is defined as all persons who purchased, for personal consumption and not for resale, one or more of the covered Neuriva products from Reckitt Benckiser or an authorized reseller in the United States, between Jan. 1, 2019, and April 23, 2021.
Williams, et al. v. Reckitt Benckiser LLC, et al., Case No. 1:20-cv-23564-MGC in the U.S. District Court for the Southern District of Florida
This settlement also resolves the following class action lawsuits:
Date Initiated: 08/26/2020
The plaintiffs in a class action lawsuit accused the defendants of falsely advertising Neuriva products as being clinically and scientifically proven to enhance brain performance, in violation of consumer protection laws and other laws.
The Class is defined as all persons who purchased, for personal consumption and not for resale, one or more of the covered Neuriva products from Reckitt Benckiser or an authorized reseller in the United States, between Jan. 1, 2019, and April 23, 2021.
Date Initiated: 04/23/2021
The Court preliminarily approved this settlement April 23, 2021.
The products covered by the settlement are all sizes of Neuriva Original, Neuriva Plus, and Deuriva De-Stress.
Without proof of purchase, Class Members may claim up to $20 — up to four purchases at $5 each.
Those who are able to provide proof of purchase may recover up to $32.50 per valid purchase, for a maximum potential award of $65.
In addition to the monetary relief, Reckitt Benckiser has agreed to change its labeling and marketing practices, including removing “clinically proven” from the labels and social media, websites, and other advertising.
The deadline to file a claim is estimated to be in April or May 2022.
